Paradigm Biopharmaceuticals Limited (ASX:PAR)
Australia flag Australia · Delayed Price · Currency is AUD
0.2420
-0.0430 (-15.09%)
Sep 11, 2026, 12:42 PM AEST

ASX:PAR Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Operating Revenue
----0.08
----0.08
Revenue Growth
----285.52%
Cost of Revenue
0.010.020.010.020.14
Gross Profit
-0.01-0.02-0.01-0.02-0.06
Selling, General & Admin
7.265.586.777.398.85
Research & Development
53.9217.7458.3352.6839.01
Operating Expenses
61.1823.3265.160.0747.87
Operating Income
-61.19-23.34-65.11-60.09-47.93
Interest Expense
-2.46-0.01-0.01-0.02-0.03
Interest & Investment Income
0.420.360.411.40.05
Currency Exchange Gain (Loss)
-0.920.01-0.05-0.390.89
Other Non Operating Income (Expenses)
7.836.756.047.097.76
EBT Excluding Unusual Items
-56.33-16.24-58.73-52-39.25
Gain (Loss) on Sale of Assets
-0.01----
Asset Writedown
--2.53---
Other Unusual Items
---0.09-
Pretax Income
-56.33-18.77-58.73-51.91-39.25
Net Income
-56.33-18.77-58.73-51.91-39.25
Net Income to Common
-56.33-18.77-58.73-51.91-39.25
Net Income Growth
-----
Shares Outstanding (Basic)
370315293250233
Shares Outstanding (Diluted)
370315293250233
Shares Change
17.66%7.23%17.43%7.34%1.21%
EPS (Basic)
-0.15-0.06-0.20-0.21-0.17
EPS (Diluted)
-0.15-0.06-0.20-0.21-0.17
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Free Cash Flow
-43.69-15.99-65.94-45.19-32.21
Free Cash Flow Per Share
-0.12-0.05-0.23-0.18-0.14
Gross Margin
-----81.45%
Operating Margin
-----60498.78%
Profit Margin
-----49542.54%
Free Cash Flow Margin
-----40650.90%
EBITDA
-61.04-23.19-64.97-59.93-47.74
D&A For EBITDA
0.150.150.150.150.19
EBIT
-61.19-23.34-65.11-60.09-47.93